Artal Group
Latest statistics and disclosures from Artal Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ARGX, LXRX, BGNE, WW, SGEN, and represent 30.80% of Artal Group's stock portfolio.
- Added to shares of these 10 stocks: C (+$46M), SRRK (+$35M), LABU (+$27M), FATE (+$15M), CYTK (+$11M), WVE (+$6.5M), CINC, Senti Biosciences Ord, SWTX, SELB.
- Started 7 new stock positions in BBWI, LABU, Senti Biosciences Ord, CINC, C, UNG, CLF.
- Reduced shares in these 10 stocks: ARGX (-$71M), SGEN (-$22M), PTGX (-$19M), SAGE (-$18M), MRTX (-$17M), INTC (-$15M), BLU (-$14M), APLS (-$10M), FMTX (-$9.3M), TGTX (-$7.6M).
- Sold out of its positions in APLS, Dynamics Special Purpose Cor, FMTX, DNA, IMCR, INTC, PTGX, TGTX, XP.
- Artal Group was a net seller of stock by $-80M.
- Artal Group has $1.9B in assets under management (AUM), dropping by -21.61%.
- Central Index Key (CIK): 0001053906
Tip: Access up to 7 years of quarterly data
Positions held by Artal Group consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for Artal Group
Artal Group holds 134 positions in its portfolio as reported in the June 2022 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Argenx Se Sponsored Adr (ARGX) | 8.1 | $152M | -31% | 400k | 378.88 | |
Lexicon Pharmaceuticals Com New (LXRX) | 7.1 | $132M | 71M | 1.86 | ||
Beigene Sponsored Adr (BGNE) | 5.6 | $105M | -2% | 650k | 161.85 | |
Ww Intl (WW) | 5.1 | $95M | 15M | 6.39 | ||
Seagen (SGEN) | 5.0 | $93M | -19% | 525k | 176.94 | |
Alnylam Pharmaceuticals (ALNY) | 4.7 | $88M | -7% | 600k | 145.85 | |
Mirati Therapeutics (MRTX) | 3.9 | $74M | -18% | 1.1M | 67.13 | |
Bellus Health Com New (BLU) | 3.5 | $65M | -17% | 7.0M | 9.24 | |
Fate Therapeutics (FATE) | 3.4 | $64M | +30% | 2.6M | 24.78 | |
Cytokinetics Com New (CYTK) | 2.7 | $50M | +27% | 1.3M | 39.29 | |
Scholar Rock Hldg Corp (SRRK) | 2.6 | $48M | +257% | 8.8M | 5.49 | |
Citigroup Com New Call Option (C) | 2.5 | $46M | NEW | 1.0M | 45.99 | |
Amicus Therapeutics (FOLD) | 2.3 | $43M | 4.0M | 10.74 | ||
Seer Com Cl A (SEER) | 2.3 | $43M | 4.8M | 8.95 | ||
Setup an alertArtal Group will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
Cerevel Therapeutics Hldng I (CERE) | 2.1 | $40M | 1.5M | 26.44 | ||
Igm Biosciences (IGMS) | 2.0 | $37M | +2% | 2.1M | 18.03 | |
Morphic Hldg (MORF) | 1.9 | $36M | 1.7M | 21.70 | ||
Krystal Biotech (KRYS) | 1.8 | $33M | 500k | 65.66 | ||
Direxion Shs Etf Tr Sp Biotch Bl New Call Option (LABU) | 1.4 | $27M | NEW | 4.0M | 6.74 | |
Foghorn Therapeutics (FHTX) | 1.2 | $23M | 1.7M | 13.60 | ||
Springworks Therapeutics (SWTX) | 1.2 | $22M | +5% | 900k | 24.62 | |
Gossamer Bio (GOSS) | 1.1 | $20M | 2.4M | 8.37 | ||
Kymera Therapeutics (KYMR) | 1.1 | $20M | 1.0M | 19.69 | ||
Kura Oncology (KURA) | 1.0 | $19M | 1.1M | 18.33 | ||
Eqrx (EQRX) | 1.0 | $19M | 4.0M | 4.69 | ||
Schrodinger (SDGR) | 1.0 | $19M | 700k | 26.41 | ||
Generation Bio (GBIO) | 1.0 | $19M | 2.8M | 6.56 | ||
Erasca (ERAS) | 0.9 | $18M | 3.2M | 5.57 | ||
Denali Therapeutics (DNLI) | 0.9 | $18M | 600k | 29.43 | ||
Replimune Group (REPL) | 0.8 | $16M | 900k | 17.48 | ||
Sage Therapeutics (SAGE) | 0.8 | $15M | -55% | 450k | 32.30 | |
Intellia Therapeutics (NTLA) | 0.8 | $14M | 275k | 51.76 | ||
Evotec Sponsored Ads (EVO) | 0.7 | $14M | 1.1M | 11.98 | ||
Relay Therapeutics (RLAY) | 0.6 | $12M | 700k | 16.75 | ||
Mersana Therapeutics (MRSN) | 0.5 | $10M | 2.2M | 4.62 | ||
Aurinia Pharmaceuticals (AUPH) | 0.5 | $10M | 1.0M | 10.05 | ||
Repare Therapeutics Ord (RPTX) | 0.5 | $9.8M | 700k | 13.99 | ||
Wave Life Sciences SHS (WVE) | 0.5 | $9.8M | +200% | 3.0M | 3.25 | |
I Mab Sponsored Ads (IMAB) | 0.5 | $9.6M | 850k | 11.30 | ||
Talaris Therapeutics (TALS) | 0.5 | $9.3M | 2.1M | 4.51 | ||
Allovir (ALVR) | 0.5 | $9.1M | 2.3M | 3.90 | ||
Omega Therapeutics (OMGA) | 0.5 | $8.6M | 2.3M | 3.80 | ||
Iteos Therapeutics (ITOS) | 0.4 | $8.2M | 400k | 20.60 | ||
Atara Biotherapeutics (ATRA) | 0.4 | $7.8M | 1.0M | 7.79 | ||
Omega Alpha Spac Cl A (OMEG) | 0.4 | $7.4M | 750k | 9.85 | ||
Ikena Oncology (IKNA) | 0.4 | $6.9M | 1.5M | 4.43 | ||
Selecta Biosciences (SELB) | 0.3 | $6.4M | +22% | 4.9M | 1.31 | |
Verve Therapeutics (VERV) | 0.3 | $6.1M | 400k | 15.28 | ||
Y Mabs Therapeutics (YMAB) | 0.3 | $6.1M | 400k | 15.13 | ||
Exscientia Ads (EXAI) | 0.3 | $6.0M | 550k | 10.89 | ||
Agenus Com New (AGEN) | 0.3 | $5.8M | -45% | 3.0M | 1.94 | |
Ambrx Biopharma Sponsored Ads (AMAM) | 0.3 | $5.7M | 2.2M | 2.65 | ||
Achilles Therapeutics Sponsored Ads (ACHL) | 0.3 | $5.7M | 2.3M | 2.52 | ||
Kronos Bio (KRON) | 0.3 | $5.6M | 1.5M | 3.64 | ||
Design Therapeutics (DSGN) | 0.3 | $5.6M | 400k | 14.00 | ||
Ovid Therapeutics (OVID) | 0.3 | $5.4M | 2.5M | 2.15 | ||
Oatly Group Ab Sponsored Ads (OTLY) | 0.3 | $5.2M | 1.5M | 3.46 | ||
Sqz Biotech (SQZ) | 0.3 | $5.1M | 1.6M | 3.18 | ||
Alpine Immune Sciences (ALPN) | 0.3 | $5.0M | 593k | 8.51 | ||
Marinus Pharmaceuticals Com New (MRNS) | 0.3 | $4.8M | 1.0M | 4.84 | ||
Contrafect Corp Com New (CFRX) | 0.2 | $4.6M | 1.5M | 3.07 | ||
Leap Therapeutics (LPTX) | 0.2 | $4.6M | 4.0M | 1.15 | ||
Lyell Immunopharma (LYEL) | 0.2 | $4.6M | 700k | 6.52 | ||
Black Diamond Therapeutics (BDTX) | 0.2 | $4.0M | 1.6M | 2.46 | ||
Alx Oncology Hldgs (ALXO) | 0.2 | $4.0M | 500k | 8.09 | ||
Taysha Gene Therapies Com Shs (TSHA) | 0.2 | $3.9M | 1.0M | 3.72 | ||
Syros Pharmaceuticals (SYRS) | 0.2 | $3.9M | +14% | 4.0M | 0.96 | |
Sea Sponsored Ads (SE) | 0.2 | $3.8M | 58k | 66.85 | ||
Nanobiotix Sponsored Ads (NBTX) | 0.2 | $3.8M | 1.0M | 3.80 | ||
Portage Fintech Acquisitn Class A Ord Shs (PFTA) | 0.2 | $3.7M | 380k | 9.75 | ||
Recursion Pharmaceuticals In Cl A (RXRX) | 0.2 | $3.7M | 450k | 8.14 | ||
Avidity Biosciences Ord (RNA) | 0.2 | $3.6M | 250k | 14.53 | ||
Ac Immune Sa SHS (ACIU) | 0.2 | $3.6M | 1.0M | 3.61 | ||
Dyne Therapeutics (DYN) | 0.2 | $3.6M | 525k | 6.87 | ||
Adverum Biotechnologies (ADVM) | 0.2 | $3.6M | 3.0M | 1.20 | ||
Aptinyx (APTX) | 0.2 | $3.4M | 6.1M | 0.56 | ||
Stoke Therapeutics (STOK) | 0.2 | $3.3M | 250k | 13.21 | ||
Adagio Therapeutics (ADGI) | 0.2 | $3.3M | 1.0M | 3.28 | ||
Cullinan Oncology (CGEM) | 0.2 | $3.2M | 250k | 12.82 | ||
Rubius Therapeutics (RUBY) | 0.2 | $3.1M | 3.7M | 0.85 | ||
Hookipa Pharma Inc equity (HOOK) | 0.2 | $3.0M | 1.8M | 1.63 | ||
Praxis Precision Medicines I (PRAX) | 0.2 | $2.9M | 1.2M | 2.45 | ||
Vigil Neuroscience (VIGL) | 0.2 | $2.9M | 1.1M | 2.58 | ||
Mirion Technologies Com Cl A (MIR) | 0.2 | $2.9M | 500k | 5.76 | ||
Vor Biopharma (VOR) | 0.1 | $2.7M | 550k | 4.97 | ||
Cincor Pharma (CINC) | 0.1 | $2.6M | NEW | 137k | 18.84 | |
Sana Biotechnology (SANA) | 0.1 | $2.6M | 400k | 6.43 | ||
Immunic (IMUX) | 0.1 | $2.4M | 700k | 3.47 | ||
Zymeworks (ZYME) | 0.1 | $2.4M | 450k | 5.30 | ||
Bridgebio Pharma (BBIO) | 0.1 | $2.3M | 250k | 9.08 | ||
Tcr2 Therapeutics Inc cs (TCRR) | 0.1 | $2.2M | 750k | 2.90 | ||
Instil Bio (TIL) | 0.1 | $2.1M | 450k | 4.62 | ||
Senti Biosciences Ord | 0.1 | $2.1M | NEW | 1.1M | 1.96 | |
Adagene Ads (ADAG) | 0.1 | $2.1M | 1.0M | 2.07 | ||
Immutep Sponsored Ads (IMMP) | 0.1 | $2.0M | 1.0M | 2.03 | ||
111 Ads (YI) | 0.1 | $2.0M | 966k | 2.06 | ||
Neximmune (NEXI) | 0.1 | $1.9M | 1.2M | 1.61 | ||
Graphite Bio (GRPH) | 0.1 | $1.9M | 700k | 2.75 | ||
Harpoon Therapeutics (HARP) | 0.1 | $1.9M | 1.0M | 1.91 | ||
Fusion Pharmaceuticals (FUSN) | 0.1 | $1.9M | 750k | 2.49 | ||
Solid Biosciences (SLDB) | 0.1 | $1.8M | 3.0M | 0.62 | ||
Gritstone Oncology Ord (GRTS) | 0.1 | $1.8M | 750k | 2.42 | ||
Oric Pharmaceuticals (ORIC) | 0.1 | $1.8M | 400k | 4.48 | ||
Mereo Biopharma Group Ads (MREO) | 0.1 | $1.7M | 1.5M | 1.12 | ||
Cardiff Oncology (CRDF) | 0.1 | $1.7M | 750k | 2.20 | ||
23andme Holding Class A Com (ME) | 0.1 | $1.6M | 661k | 2.48 | ||
Kinnate Biopharma (KNTE) | 0.1 | $1.6M | 125k | 12.61 | ||
Cyclerion Therapeutics (CYCN) | 0.1 | $1.5M | 2.8M | 0.55 | ||
Axcella Health Inc equity (AXLA) | 0.1 | $1.4M | 713k | 2.03 | ||
Amylyx Pharmaceuticals (AMLX) | 0.1 | $1.4M | 75k | 19.27 | ||
Xilio Therapeutics (XLO) | 0.1 | $1.3M | 450k | 2.92 | ||
Aravive (ARAV) | 0.1 | $1.3M | 1.3M | 0.99 | ||
Curis Com New (CRIS) | 0.1 | $1.3M | 1.3M | 0.98 | ||
Ironwood Pharmaceuticals Com Cl A (IRWD) | 0.1 | $1.3M | 111k | 11.53 | ||
Olema Pharmaceuticals (OLMA) | 0.1 | $1.1M | 261k | 4.07 | ||
Orchard Therapeutics Ads (ORTX) | 0.1 | $1.1M | 1.8M | 0.58 | ||
Mei Pharma Com New (MEIP) | 0.0 | $605k | 1.0M | 0.60 | ||
Lava Therapeutics Nv SHS (LVTX) | 0.0 | $590k | 200k | 2.95 | ||
Codiak Biosciences (CDAK) | 0.0 | $576k | 200k | 2.88 | ||
Caribou Biosciences (CRBU) | 0.0 | $572k | 105k | 5.43 | ||
Hippo Holdings (HIPO) | 0.0 | $527k | 600k | 0.88 | ||
Corvus Pharmaceuticals (CRVS) | 0.0 | $495k | 500k | 0.99 | ||
Metacrine Ord (MTCR) | 0.0 | $462k | 925k | 0.50 | ||
Mink Therapeutics (INKT) | 0.0 | $408k | 290k | 1.41 | ||
Yumanity Therapeutics (YMTX) | 0.0 | $396k | 217k | 1.82 | ||
Cleveland-cliffs (CLF) | 0.0 | $384k | NEW | 25k | 15.36 | |
United Sts Nat Gas Unit Par (UNG) | 0.0 | $380k | NEW | 20k | 19.00 | |
Applied Therapeutics (APLT) | 0.0 | $379k | 400k | 0.95 | ||
Spero Therapeutics (SPRO) | 0.0 | $371k | 500k | 0.74 | ||
Bath & Body Works In (BBWI) | 0.0 | $337k | NEW | 13k | 26.96 | |
Sigilon Therapeutics (SGTX) | 0.0 | $229k | 276k | 0.83 | ||
Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.0 | $110k | 225k | 0.49 | ||
Astria Therapeutics (ATXS) | 0.0 | $100k | 33k | 3.00 | ||
Kaleido Biosciences Ord (KLDO) | 0.0 | $31k | 501k | 0.06 |
Past Filings by Artal Group
SEC 13F filings are viewable for Artal Group going back to 2012
- Artal Group 2022 Q2 filed Aug. 11, 2022
- Artal Group 2022 Q1 filed May 12, 2022
- Artal Group 2021 Q4 filed Feb. 11, 2022
- Artal Group 2021 Q3 filed Nov. 12, 2021
- Artal Group 2021 Q2 filed Aug. 13, 2021
- Artal Group 2021 Q1 filed May 14, 2021
- Artal Group 2020 Q4 filed Feb. 11, 2021
- Artal Group 2020 Q3 filed Nov. 13, 2020
- Artal Group 2020 Q2 filed Aug. 14, 2020
- Artal Group 2020 Q1 filed May 14, 2020
- Artal Group 2019 Q4 filed Feb. 13, 2020
- Artal Group 2019 Q3 filed Nov. 14, 2019
- Artal Group 2019 Q2 filed Aug. 9, 2019
- Artal Group 2019 Q1 filed May 10, 2019
- Artal Group 2018 Q4 filed Feb. 11, 2019
- Artal Group 2018 Q3 filed Nov. 9, 2018